Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Icon (ICLR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cabaletta Bio (CABA – Research Report) and Icon (ICLR – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Cabaletta Bio (CABA)

In a report issued on October 8, Phil Nadeau from TD Cowen maintained a Buy rating on Cabaletta Bio. The company’s shares closed last Monday at $2.48, close to its 52-week low of $1.45.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 7.0% and a 45.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, BioMarin Pharmaceutical, and Apellis Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $12.00 average price target, implying a 393.8% upside from current levels. In a report issued on September 23, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15.00 price target.

See the top stocks recommended by analysts >>

Icon (ICLR)

Leerink Partners analyst Michael Cherny reiterated a Buy rating on Icon on October 8. The company’s shares closed last Monday at $186.98, close to its 52-week low of $174.93.

According to TipRanks.com, Cherny is a 4-star analyst with an average return of 5.2% and a 57.5% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Quest Diagnostics, and Envista Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Icon with a $210.00 average price target, a 14.4% upside from current levels. In a report issued on October 8, Evercore ISI also maintained a Buy rating on the stock with a $240.00 price target.

Read More on CABA:

Disclaimer & DisclosureReport an Issue

• 3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts
• Promising Potential of Cabaletta Bio’s Rese-cel Therapy Drives Buy Rating
• Promising Early Data from Cabaletta Bio’s Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment
• Cabaletta Bio jumps 30% to $3.13 after pemphigus vulgaris data
• Cabaletta Bio Presents Promising RESET-PV Trial Data